Key facts
- Glyphic Biotechnologies’s last known valuation is $155.0M (Sep 2025).
- It has raised $43.8M; the latest was Early Stage VC in Sep 2025.
- Notable investors include Gaingels, Calm Ventures, Valor Equity Partners, SBXi, Johnson & Johnson Innovation - JLABS — 35 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 35 names
- ·Watchlist + deal alerts for Glyphic Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Glyphic Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glyphic Biotechnologies
Operator of a biotechnology platform intended to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds. The company's platform focuses on developing a single-molecule, massively parallel, de novo next-generation protein sequencing platform, enabling scientists and researchers to develop novel therapeutics and diagnostics and ultimately understand human biology and disease.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2021
- Employees
- 30
- Website
- glyphic.bio/
- Ownership
- Privately Held (backing)
Glyphic Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glyphic Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glyphic Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.